Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review

Lombardo, Gérôme; Lechanteur, Chantal; Briquet, Alexandra; Seidel, Laurence; Willems, Evelyne; Servais, Sophie; Baudoux, Etienne; Kerre, Tessa; Zachee, Pierre; Herman, Julie; Janssen, Audrey; Muller, Joséphine; Baron, Frédéric; Beguin, Yves

doi:10.1186/s13287-024-04064-w

Stem Cell Research & Therapy

Table 2 Patient outcomes after transplantation

From: Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review

			Placebo	MSC	P value
Kaplan–Meier overall survival	1 year	Rate	80%	74%	0.64
Kaplan–Meier overall survival	5 years	Rate	58%	44%
Kaplan–Meier progression-free survival	1 year	Rate	80%	65%	0.41
Kaplan–Meier progression-free survival	5 years	Rate	42%	33%
Cumulative incidence of relapse	1 year	Rate	21%	23%	0.59
Cumulative incidence of relapse	5 years	Rate	32%	41%
Cause of death (hemopathy/GVHD/other)		Number	3/3/0	4/3/5	0.63
aGVHD
Grade 1/2/3/4		Number	1/4/2/2	2/6/2/1	0.87
100-d cumulative incidence of aGVHR, grades II-IV		Rate	53%	30%	0.15
100-d cumulative incidence of aGVHR, grades III-IV		Rate	27%	9%	0.13
aGVHD resolution (CR/no CR)		Number	6/3	6/5	0.67
cGVHD
Mild/Moderate/Severe		Number	2/2/4	4/5/3	0.71
5-yr cumulative incidence of cGVHR, overall		Rate	67%	48%	0.27
5-yr cumulative incidence of cGVHR, moderate/severe		Rate	40%	30%	0.56
cGVHD resolution (CR/no CR)		Number	2/6	5/7	0.44
Donor engraftment (no/yes)		Number	0/15	0/23	1
Chimemism (full donor/other)*		Number	13/1	22/1	0.72
T lymphocyte count on day 30, median		/µL	530	363	0.56
Neutrophil recovery (complete/partial)		Number	15/0	23/0	0.19
Median time to 1,000 PMN/µL		Days	13	17	0.0174
Red blood cell recovery (complete/partial or none)*		Number	11/3	14/4	0.96
Median time to hemoglobin > 10 g/dl		Days	59	73	0.94
Red blood cell transfusions days 0–30, median		Number	1	1	0.57
Median time to RBC transfusion independence		Days	16	22	0.57
Platelet recovery (complete/partial or none)		Number	13/2	22/1	0.32
Median time to 50,000 platelets/µL		Days	11	11	0.93
Median time to 100,000 platelets/µL		Days	14	16	0.54
Platelet count on day 30, median		10³/µL	100	134	0.14
Platelet transfusions days 0–30, median		Number	0	0	0.31
Infections
Cumulative incidence of infection		Rate	80%	91%	0.29
Cumulative incidence of sepsis		Rate	33%	44%	0.37
Cumulative incidence of CMV infection		Rate	33%	35%	0.82
Cumulative incidence of other infections		Rate	80%	87%	0.59
Second cancer (no/yes)		Number	14/1	20/3	0.53

^* = not all patients are evaluable

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: journalsubmissions@springernature.com